Endogenous hormones and ovarian cancer: Epidemiology and current hypotheses

Cancer Epidemiology Biomarkers and Prevention

Volumn 14, Issue 1, 2005, Pages 98-107

  Lukanova, Annekatrin ^a   Kaaks, Rudolf ^b  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; ESTROGEN; GONADOTROPIN; INSULIN; PROGESTERONE; SEX HORMONE; SOMATOMEDIN C;

AGE DETERMINATION; CANCER DIAGNOSIS; CANCER RISK; CELL DIFFERENTIATION; FAMILY HISTORY; FEMALE; FEMALE INFERTILITY; HORMONAL CARCINOGENESIS; HORMONAL THERAPY; HUMAN; HYPERINSULINEMIA; HYSTERECTOMY; OBESITY; ORAL CONTRACEPTION; OVARY CANCER; OVARY CYST; POSTMENOPAUSE; PREGNANCY; PRIORITY JOURNAL; REVIEW; RISK FACTOR; STEROIDOGENESIS; UTERINE TUBE LIGATION;

FEMALE; GONADAL STEROID HORMONES; HUMANS; INCIDENCE; OVARIAN NEOPLASMS; RISK FACTORS;

EID: 12844284531     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (201)

1. Ferlay J, Bray F, Pisani P, Parkin DM. GLOBOCAN 2000: cancer incidence, mortality and prevalence worldwide. Version 1.0. Lyon (France): IARC Press; 2001.
2. Parkin DM, Whelan SL, Ferlay J, Teppo L, Thomas DB. Cancer incidence in five continents. VIII. Lyon (France): IARC Press; 2002.
3. Antoniou A, Pharoah PD, Narod S, et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet 2003;72:1117-30.
4. Weiss NS, Cook LS, Farrow DC, Rosenblatt KA. Ovarian cancer. In: Schottenfeld D, Fraumeni FJ, editors. Cancer epidemiology and prevention. New York: Oxford University Press; 1996. p. 1040-57.
5. Chen VW, Ruiz B, Killeen JL, Cote TR, Wu XC, Correa CN. Pathology and classification of ovarian tumors. Cancer 2003;97:2631-42.
6. Tung KH, Goodman MT, Wu AH, et al. Reproductive factors and epithelial ovarian cancer risk by histologic type: a multiethnic case-control study. Am J Epidemiol 2003;158:629-38.
7. Albrektsen G, Heuch I, Kvale G. Full-term pregnancies and incidence of ovarian cancer of stromal and germ cell origin: a Norwegian prospective study. Br J Cancer 1997;75:767-70.
8. Scully RE. Pathology of ovarian cancer precursors. J Cell Biochem Suppl 1995;23:208-18.
9. Scully RE. Ovarian tumors. A review. Am J Pathol 1977;87:686-720.
10. Risch HA, Marrett LD, Jain M, Howe GR. Differences in risk factors for epithelial ovarian cancer by histologic type. Results of a case-control study. Am J Epidemiol 1996;144:363-72.
11. Purdie DM, Siskind V, Bain CJ, Webb PM, Green AC. Reproduction-related risk factors for mucinous and nonmucinous epithelial ovarian cancer. Am J Epidemiol 2001;153:860-4.
12. Wittenberg J, Cook LS, Rossing MA, Weiss NS, Wittenberg L. Reproductive risk factors for mucinous and non-mucinous epithelial ovarian cancer. Epidemiology 1999;10:761-3.
13. Riman T, Dickman PW, Nilsson S, et al. Risk factors for invasive epithelial ovarian cancer: results from a Swedish case-control study. Am J Epidemiol 2002;156:363-73.
14. Seidman JD, Russell P, Kurman RJ. Surface epithelial tumors of the ovary. In: Kurman RJ, editor. Blaustein's pathology of the female genital tract. New York: Springer-Verlag; 2002. p. 791-904.
15. Riman T, Dickman PW, Nilsson S, et al. Risk factors for epithelial borderline ovarian tumors: results of a Swedish case-control study. Gynecol Oncol 2001;83:575-85.
16. Seidman JD, Kurman RJ. Pathology of ovarian carcinoma. Hematol Oncol Clin North Am 2003;17:909-25.
17. Harris R, Whittemore AS, Itnyre J. Characteristics relating to ovarian cancer risk: collaborative analysis of 12 US case-control studies. III. Epithelial tumors of low malignant potential in white women. Collaborative Ovarian Cancer Group. Am J Epidemiol 1992;136:1204-11.
18. Herrinton LJ, Stanford JL, Schwartz SM, Weiss NS. Ovarian cancer incidence among Asian migrants to the United States and their descendants. J Natl Cancer Inst 1994;86:1336-9.
19. Kliewer EV, Smith KR. Ovarian cancer mortality among immigrants in Australia and Canada. Cancer Epidemiol Biomarkers Prev 1995;4:453-8.
20. Le GM, Gomez SL, Clarke CA, Glaser SL, West DW. Cancer incidence patterns among Vietnamese in the United States and Ha Noi, Vietnam. Int J Cancer 2002;102:412-7.
21. Risch HA. Hormonal etiology of epithelial ovarian cancer, with a hypothesis concerning the role of androgens and progesterone. J Natl Cancer Inst 1998;90:1774-86.
22. Banks E, Beral V, Reeves G. The epidemiology of epithelial ovarian cancer: a review. Int J Gynecol Cancer 1997;7:425-38.
23. Whittemore AS, Harris R, Itnyre J. Characteristics relating to ovarian cancer risk: collaborative analysis of 12 US case-control studies. II. Invasive epithelial ovarian cancers in white women. Collaborative Ovarian Cancer Group. Am J Epidemiol 1992;136:1184-203.
24. Hankinson SE, Colditz GA, Hunter DJ, et al. A prospective study of reproductive factors and risk of epithelial ovarian cancer. Cancer 1995;76:284-90.
25. Kvale G, Heuch I, Nilssen S, Beral V. Reproductive factors and risk of ovarian cancer: a prospective study. Int J Cancer 1988;42:246-51.
26. Modugno F, Ness RB, Wheeler JE. Reproductive risk factors for epithelial ovarian cancer according to histologic type and invasiveness. Ann Epidemiol 2001;11:568-74.
27. Adami HO, Hsieh CC, Lambe M, et al. Parity, age at first childbirth, and risk of ovarian cancer. Lancet 1994;344:1250-4.
28. Titus-Ernstoff L, Perez K, Cramer DW, Harlow BL, Baron JA, Greenberg ER. Menstrual and reproductive factors in relation to ovarian cancer risk. Br J Cancer 2001;84:714-21.
29. Cooper GS, Schildkraut JM, Whittemore AS, Marchbanks PA. Pregnancy recency and risk of ovarian cancer. Cancer Causes Control 1999;10:397-402.
30. Whiteman DC, Siskind V, Purdie DM, Green AC. Timing of pregnancy and the risk of epithelial ovarian cancer. Cancer Epidemiol Biomarkers Prev 2003;12:42-6.
31. IARC Working Group on the Evaluation of Carcinogenic Risks in Humans. Hormonal contraception and postmenopausal hormonal therapy. IARC Monograph 72. Lyon (France): IARC Press; 1999.
32. Whittemore AS. Characteristics relating to ovarian cancer risk: implications for prevention and detection. Gynecol Oncol 1994;55:515-9.
33. Hankinson SE, Colditz GA, Hunter DJ, Spencer TL, Rosner B, Stampfer MJ. A quantitative assessment of oral contraceptive use and risk of ovarian cancer. Obstet Gynecol 1992;80:708-14.
34. Franceschi S, Parazzini F, Negri E, et al. Pooled analysis of 3 European case-control studies of epithelial ovarian cancer. III. Oral contraceptive use. Int J Cancer 1991;49:61-5.
35. Ness RB, Grisso JA, Klapper J, et al. Risk of ovarian cancer in relation to estrogen and progestin dose and use characteristics of oral contraceptives. SHARE Study Group. Steroid Hormones and Reproductions. Am J Epidemiol 2000;152:233-41.
36. Bosetti C, Negri E, Trichopoulos D, et al. Long-term effects of oral contraceptives on ovarian cancer risk. Int J Cancer 2002;102:262-5.
37. Coughlin SS, Giustozzi A, Smith SJ, Lee NC. A meta-analysis of estrogen replacement therapy and risk of epithelial ovarian cancer. J Clin Epidemiol 2000;53:367-75.
38. Garg PP, Kerlikowske K, Subak L, Grady D. Hormone replacement therapy and the risk of epithelial ovarian carcinoma: a meta-analysis. Obstet Gynecol 1998;92:472-9.
39. Rodriguez C, Patel AV, Calle EE, Jacob EJ, Thun MJ. Estrogen replacement therapy and ovarian cancer mortality in a large prospective study of US women. JAMA 2001;285:1460-5.
40. Lacey JV Jr, Mink PJ, Lubin JH, et al. Menopausal hormone replacement therapy and risk of ovarian cancer. JAMA 2002;288:334-41.
41. Folsom AR, Anderson JP, Ross JA. Estrogen replacement therapy and ovarian cancer. Epidemiology 2004;15:100-4.
42. Riman T, Dickman PW, Nilsson S, et al. Hormone replacement therapy and the risk of invasive epithelial ovarian cancer in Swedish women. J Natl Cancer Inst 2002;94:497-504.
43. Anderson GL, Judd HL, Kaunitz AM, et al. Effects of estrogen plus progestin on gynecologic cancers and associated diagnostic procedures: the Women's Health Initiative randomized trial. JAMA 2003;290:1739-48.
44. Chiaffarino F, Pelucchi C, Parazzini F, et al. Reproductive and hormonal factors and ovarian cancer. Ann Oncol 2001;12:337-41.
45. Sit AS, Modugno F, Weissfeld JL, Berga SL, Ness RB, Hormone replacement therapy formulations and risk of epithelial ovarian carcinoma. Gynecol Oncol 2002;86:118-23.
46. Risch HA. Hormone replacement therapy and the risk of ovarian cancer. Gynecol Oncol 2002;86:115-7.
47. Riman T. Hormone replacement therapy and epithelial ovarian cancer: is there and association? J Br Menopause Soc 2003;9:61-8.
48. Lambe M, Wuu J, Rossing MA, Hsieh CC. Twinning and maternal risk of ovarian cancer. Lancet 1999;353:1941.
49. Whiteman DC, Murphy MF, Cook LS, et al. Multiple births and risk of epithelial ovarian cancer. J Natl Cancer Inst 2000;92:1172-7.
50. La Vecchia C, Negri E, Talamini R, Conti E, Montella M, Franceschi S. Re: Multiple births and risk of epithelial ovarian cancer. J Natl Cancer Inst 2001;93:319-20.
51. Schildkraut JM, Schwingl PJ, Bastos E, Evanoff A, Hughes C. Epithelial ovarian cancer risk among women with polycystic ovary syndrome. Obstet Gynecol 1996;88:554-9.
52. Brinton LA, Gridley G, Persson I, Baron J, Bergqvist A. Cancer risk after a hospital discharge diagnosis of endometriosis. Am J Obstet Gynecol 1997;176:572-9.
53. Ness RB, Grisso JA, Cottreau C, et al. Factors related to inflammation of the ovarian epithelium and risk of ovarian cancer. Epidemiology 2000;11:111-7.
54. Ness RB. Endometriosis and ovarian cancer: thoughts on snared pathophysiology. Am J Obstet Gynecol 2003;189:280-94.
55. Purdie D, Green A, Bain C, et al. Reproductive and other factors and risk of epithelial ovarian cancer: an Australian case-control study. Survey of Women's Health Study Group. Int J Cancer 1995;62:678-84.
56. Schildkraut JM, Cooper GS, Halabi S, Calingaert B, Hartge P, Whittemore AS. Age at natural menopause and the risk of epithelial ovarian cancer. Obstet Gynecol 2001;98:85-90.
57. Ness RB, Cramer DW, Goodman MT, et al. Infertility, fertility drugs, and ovarian cancer: a pooled analysis of case-control studies. Am J Epidemiol 2002;155:217-24.
58. Klip H, Burger CW, Kenemans P, van Leeuwen FE. Cancer risk associated with subfertility and ovulation induction: a review. 2000;11:319-44.
59. Modan B, Ron E, Lerner GL, et al. Cancer incidence in a cohort of infertile women. Am J Epidemiol 1998;147:1038-42.
60. Glud E, Kjaer SK, Troisi R, Brinton LA. Fertility drugs and ovarian cancer. Epidemiol Rev 1998;20:237-57.
61. Rodriguez C, Calle EE, Fakhrabadi-Shokoohi D, Jacobs EJ, Thun MJ. Body mass index, height, and the risk of ovarian cancer mortality in a prospective cohort of postmenopausal women. Cancer Epidemiol Biomarkers Prev 2002;11:822-8.
62. Purdie DM, Bain CJ, Webb PM, Whiteman DC, Pirozzo S, Green AC. Body size and ovarian cancer: case-control study and systematic review (Australia). Cancer Causes Control 2001;12:855-63.
63. Wolk A, Gridley G, Svensson M, et al. A prospective study of obesity and cancer risk (Sweden). Cancer Causes Control 2001;12:13-21.
64. Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med 2003;348:1625-38.
65. Vainio H, Bianchini F, editors. In: Weight control and physical activity. Lyon (France): IARC Press; 2002.
66. Fairfield KM, Willett WC, Rosner BA, Manson JE, Speizer FE, Hankinson SE. Obesity, weight gain, and ovarian cancer. Obstet Gynecol 2002;100:288-96.
67. Kuper H, Cramer DW, Titus-Ernstoff L. Risk of ovarian cancer in the United States in relation to anthropometric measures: does the association depend on menopausal status? Cancer Causes Control 2002;13:455-63.
68. Mink PJ, Folsom AR, Sellers TA, Kushi LH. Physical activity, waist-to-hip ratio, and other risk factors for ovarian cancer: a follow-up study of older women. Epidemiology 1996;7:38-45.
69. Dal Maso L, Franceschi S, Negri E, et al. Body size indices at different ages and epithelial ovarian cancer risk. Eur J Cancer 2002;38:1769-74.
70. Beard CM, Hartmann LC, Atkinson EJ, et al. The epidemiology of ovarian cancer: a population-based study in Olmsted County, Minnesota, 1935-1991. Ann Epidemiol 2000;10:14-23.
71. Anderson JP, Ross JA, Folsom AR. Anthropometric variables, physical activity, and incidence of ovarian cancer: the Iowa Women's Health Study. Cancer 2004;100:1515-21.
72. Engeland A, Tretli S, Bjorge T. Height, body mass index, and ovarian cancer: a follow-up of 1.1 million Norwegian women. J Natl Cancer Inst 2003;95:1244-8.
73. Parazzini F, Moroni S, La Vecchia C, Negri E, dal Pino D, Bolis G. Ovarian cancer risk and history of selected medical conditions linked with female hormones. Eur J Cancer 1997;33:1634-7.
74. Lukanova A, Toniolo P, Lundin E, et al. Body mass index in relation to ovarian cancer: a multi-centre nested case-control study. Int J Cancer 2002;99:603-8.
75. Lubin F, Chetrit A, Freedman LS, et al. Body mass index at age 18 years and during adult life and ovarian cancer risk. Am J Epidemiol 2003;157:113-20.
76. Schouten LJ, Goldbohm RA, van den Brandt PA. Height, weight, weight change, and ovarian cancer risk in the Netherlands cohort study on diet and cancer. Am J Epidemiol 2003;157:424-33.
77. Jonsson F, Wolk A, Pedersen NL, et al. Obesity and hormone-dependent tumors: cohort and co-twin control studies based on the Swedish Twin Registry. Int J Cancer 2003;106:594-9.
78. Sonnichsen AC, Lindlacher U, Richter WO, Schwandt P. Obesity, body fat distribution and the incidence of breast, cervical, endometrial and ovarian carcinomas [in German]. Dtsch Med Wochenschr 1990;115:1906-10.
79. Zhang M, Lee AH, Binns CW. Physical activity and epithelial ovarian cancer risk: a case-control study in China Int J Cancer 2003;105:838-43.
80. Bertone ER, Willett WC, Rosner BA, et al. Prospective study of recreational physical activity and ovarian cancer. J Natl Cancer Inst 2001;93:942-8.
81. Bertone ER, Newcomb PA, Willett WC, Stampfer MJ, Egan KM. Recreational physical activity and ovarian cancer in a population-based case-control study. Int J Cancer 2002;99:431-6.
82. Terry PD, Miller AB, Jones JG, Rohan TE. Cigarette smoking and the risk of invasive epithelial ovarian cancer in a prospective cohort study. Eur J Cancer 2003;39:1157-64.
83. Green A, Purdie D, Bain C, Siskind V, Webb PM. Cigarette smoking and risk of epithelial ovarian cancer (Australia). Cancer Causes Control 2001; 12:713-9.
84. Modugno F, Ness RB, Cottreau CM. Cigarette smoking and the risk of mutinous and nonmucinous epithelial ovarian cancer. Epidemiology 2002;13:467-71.
85. Marchbanks PA, Wilson H, Bastos E, Cramer DW, Schildkraut JM, Peterson HB. Cigarette smoking and epithelial ovarian cancer by histologic type. Obstet Gynecol 2000;95:255-60.
86. Fathalla MF. Incessant ovulation - a factor in ovarian neoplasia? Lancet 1971;2:163.
87. Ness RB, Cottreau C. Possible role of ovarian epithelial inflammation in ovarian cancer. J Natl Cancer Inst 1999;91:1459-67.
88. Cramer DW, Xu H. Epidemiologic evidence for uterine growth factors in the pathogenesis of ovarian cancel. Ann Epidemiol 1995;5:310-4.
89. Purdie DM, Bain CJ, Siskind V, Webb PM, Green AC. Ovulation and risk of epithelial ovarian cancer. Int J Cancer 2003;104:228-32.
90. Moorman PG, Schildkraut JM, Calingaert B, Halabi S, Vine MF, Berchuck A. Ovulation and ovarian cancer: a comparison of two methods for calculating lifetime ovulatory cycles (United States). Cancer Causes Control 2002;13:807-11.
91. Feeley KM, Wells M. Precursor lesions of ovarian epithelial malignancy. Histopathology 2001;38:87-95.
92. Auersperg N, Wong AS, Choi KC, Kang SK, Leung PC. Ovarian surface epithelium: biology, endocrinology, and pathology. Endocr Rev 2001;22:255-88.
93. Aueisperg N, Edelson MI, Mok SC, Johnson SW, Hamilton TC. The biology of ovarian cancer. Semin Oncol 1998;25:281-304.
94. Dyck HG, Hamilton TC, Godwin AK, Lynch HT, Maines-Bandiera S, Auersperg N. Autonomy of the epithelial phenotype in human ovarian surface epithelium: changes with neoplastic progression and with a family history of ovarian cancer. Int J Cancer 1996;69:429-36.
95. Heller DS, Hameed M, Baergen R. Lack of proliferative activity of surface epithelial inclusion cysts of the ovary. Int J Gynecol Cancer 2003;13:303-7.
96. Ferenczy A, Bertrand G, Gelfand MM. Proliferation kinetics of human endometrium during the normal menstrual cycle. Am J Obstet Gynecol 1979;133:859-67.
97. Mittal KR, Zeleniuch-Jacquotte A, Cooper JL, Demopoulos RI. Contralateral ovary in unilateral ovarian carcinoma: a search for preneoplastic lesions. Int J Gynecol Pathol 1993;12:59-63.
98. Blaustein A, Kaganowicz A, Wells J. Tumor markers in inclusion cysts of the ovary. Cancer 1982;49:722-6.
99. Cordon-Cardo C, Mattes MJ, Melamed MR, Lewis JL Jr, Old LJ, Lloyd KO. Immunopathologic analysis of a panel of mouse monoclonal antibodies reacting with human ovarian carcinomas and other human tumors. Int. J Gynecol Pathol 1985;4:121-30.
100. Nouwen EJ, Hendrix PG, Dauwe S, Eerdekens MW, De Broe ME. Tumor markers in the human ovary and its neoplasms. A comparative immunohistochemical study. Am J Pathol 1987;126:230-42.
101. Kabawat SE, Bast RC Jr, Bhan AK, Welch WR, Knapp RC, Colvin RB. Tissue distribution of a coelomic-epithelium-related antigen recognized by the monoclonal antibody OC125. Int J Gynecol Pathol 1983;2:275-85.
102. Radisavljevic SV. The pathogenesis of ovarian inclusion cysts and cystomas. Obstet Gynecol 1977;49:424-9.
103. Clement P. Non-neoplastic lesions of the ovary. In: RJ Kurman, editor. Blaustein's pathology of the female genital tract. New York: Springer-Verlag; 2002. p. 675-727.
104. Resta L, Scordari MD, Colucci GA, et al. Morphological changes of the ovarian surface epithelium in women with ovarian polycystic disease or endometrial carcinoma and a control group. Eur. J Gynaecol Oncol 1989;10:39-41.
105. Hamilton TC. Ovarian cancer. Part I. Biology. Curr Probl Cancer 1992;16:1-57.
106. Godwin AK, Perez RP, Johnson SW, Hamaguchi K, Hamilton TC. Growth regulation of ovarian cancer. Hematol Oncol Clin North Am 1992;6:829-41.
107. Cramer DW, Welch WR. Determinants of ovarian cancer risk. II. Inferences regarding pathogenesis. J Natl Cancer Inst 1983;71:717-21.
108. Ames BN, Shigenaga MK, Gold LS. DNA lesions, inducible DNA repair, and cell division: three key factors in mutagenesis and carcinogenesis. Environ Health Perspect 1993;101:35-44.
109. Preston-Martin S, Pike MC, Ross RK, Jones PA, Henderson BE. Increased cell division as a cause of human cancer. Cancer Res 1990;50:7415-21.
110. Russo J, Tay LK, Russo H. Differentiation of the mammary gland and susceptibility to carcinogenesis. Breast Cancer Res Treat 1982;2:5-73.
111. Rao BR, Slotman BJ. Endocrine factors in common epithelial ovarian cancer. Endocr Rev 1991;12:14-26.
112. Helzlsouer KJ, Alberg AJ, Gordon GB, et al. Serum gonadotropins and steroid hormones and the development of ovarian cancer. JAMA 1995;274:1926-30.
113. Akhmedkhanov A, Toniolo P, Zeleniuch-Jacquotte A, Pettersson KS, Huhtaniemi IT. Luteinizing hormone, its β-subunit variant, and epithelial ovarian cancer: the gonadotropin hypothesis revisited. Am J Epidemiol 2001;154:43-9.
114. Lukanova A, Lundin E, Toniolo P, et al. Circulating levels of insulin-like growth factor-I and risk of ovarian cancer. Int J Cancer 2002;101:549-54.
115. Choi KC, Kang SK, Tai CJ, Auersperg N, Leung PC. Follicle-stimulating hormone activates mitogen-activated protein kinase in preneoplastic and neoplastic ovarian surface epithelial cells. J Clin Endocrinol Metab 2002;87:2245-53.
116. Syed V, Ulinski G, Mok SC, Yiu GK, Ho SM. Expression of gonadotropin receptor and growth responses to key reproductive hormones in normal and malignant human ovarian surface epithelial cells. Cancer Res 2001;61:6768-76.
117. Zheng W, Lu JJ, Luo F, et al. Ovarian epithelial tumor growth promotion by follicle-stimulating hormone and inhibition of the effect by luteinizing hormone. Gynecol Oncol 2000;76:80-8.
118. Ivarsson K, Sundfeldt K, Brannstrom M, Hellberg P, Janson PO. Diverse effects of FSH and LH on proliferation of human ovarian surface epithelial cells. Hum Reprod 2001;16:18-23.
119. Stakleff KD, Von Gruenigen VE. Rodent models for ovarian cancer research. Int J Gynecol Cancer 2003;13:405-12.
120. Martin NG, Robertson DM, Chenevix-Trench G, de Kretser DM, Osborne J, Burger HG. Elevation of follicular phase inhibin and luteinizing hormone levels in mothers of dizygotic twins suggests nonovarian control of human multiple ovulation. Fertil Steril 1991;56:469-74.
121. Lambalk CB, Boomsma DI, De Boer L, et al. Increased levels and pulsatility of follicle-stimulating hormone in mothers of hereditary dizygotic twins. J Clin Endocrinol Metab 1998;83:481-6.
122. Bohlke K, Cramer DW, Barbieri RL. Relation of luteinizing hormone levels to body mass index in premenopausal women. Fertil Steril 1998;69:500-4.
123. Cramer DW, Barbieri RL, Fraer AR, Harlow BL. Determinants of early follicular phase gonadotrophin and estradiol concentrations in women of late reproductive age. Hum Reprod 2002;17:221-7.
124. Arslan AA, Zeleniuch-Jacquotte A, Lundin E, et al. Serum follicle-stimulating hormone and risk of epithelial ovarian cancer in postmenopausal women. Cancer Epidemiol Biomarkers Prev 2003;12:1531-5.
125. Burger HG. Androgen production in women. Fertil Steril 2002;77:3-5.
126. Hormone biosynthesis, metabolism, and mechanism of action. In: Speroff L, Glass RH, Kase NG, editors. Clinical gynecologic endocrinology and infertility. Baltimore (MD): Williams & Wilkins; 1994. p. 31-92.
127. Carr BR. Disorders of the ovary and female reproductive tract. In: Wilson JD, Foster DW, editors. William's textbook of endocrinology. Philadelphia (PA): W.B. Saunders Co.; 1998. p. 733-98, 1221.
128. Adashi EY. The climacteric ovary as a functional gonadotropin-driven androgen-producing gland. Fertil Steril 1994;62:20-7.
129. Laughlin GA, Barrett-Connor E, Kritz-Silverstein D, von Muhlen D. Hysterectomy, oophorectomy, and endogenous sex hormone levels in older women: the Rancho Bernardo Study. J Clin Endocrinol Metab 2000;85:645-51.
130. Sluijmer AV, Heineman MJ, de Jong FH, Evers JL. Endocrine activity of the postmenopausal ovary: the effects of pituitary down-regulation and oophorectomy. J Clin Endocrinol Metab 1995;80:2163-7.
131. Edmondson RJ, Monaghan JM, Davies BR. The human ovarian surface epithelium is an androgen responsive tissue. Br J Cancer 2002;86:879-85.
132. Karlan BY, Jones J, Greenwald M, Lagasse LD. Steroid hormone effects on the proliferation of human ovarian surface epithelium in vitro. Am J Obstet Gynecol 1995;173:97-104.
133. Silva EG, Tornos C, Fritsche HA Jr, et al. The induction of benign epithelial neoplasms of the ovaries of guinea pigs by testosterone stimulation: a potential animal model. Mod Pathol 1997;10:879-83.
134. Wiegratz I, Jung-Hoffmann C, Kuhl H. Effect of two oral contraceptives containing ethinylestradiol and gestodene or norgestimate upon androgen parameters and serum binding proteins. Contraception 1995;51:341-6.
135. Coenen CM, Thomas CM, Borm GF, Hollanders JM, Rolland R. Changes in androgens during treatment with four low-dose contraceptives. Contraception 1996;53:171-6.
136. Falsetti L, Gambera A, Tisi G. Efficacy of the combination ethinyl oestradiol and cyproterone acetate on endocrine, clinical and ultrasonographic profile in polycystic ovarian syndrome. Hum Reprod 2001;16:36-42.
137. Nobels F, Dewailly D. Puberty and polycystic ovarian syndrome: the insulin/insulin-like growth factor I hypothesis. Fertil Steril 1992;58:655-66.
138. Yen SSC. Chronic anovulation caused by peripheral endocrine disorders. In: Yen SSC, Jaffe RB, editors. Reproductive endocrinology: physiology, pathophysiology, and clinical management. Philadelphia (PA): W.B. Saunders Co.; 1991. p. 576-629.
139. Morales AJ, Laughlin GA, Butzow T, Maheshwari H, Baumann G, Yen SS. Insulin, somatotropic, and luteinizing hormone axes in lean and obese women with polycystic ovary syndrome: common and distinct features. J Clin Endocrinol Metab 1996;81:2854-64.
140. Lukanova A, Lundin E, Akhmedkhanov A, et al. Circulating levels of sex steroid hormones and risk of ovarian cancer. Int J Cancer 2003; 104:636-42.
141. Blaustein A, Lee H. Surface cells of the ovary and pelvic peritoneum: a histochemical and ultrastructure comparison. Gynecol Oncol 1979;8:34-43.
142. McNatty KP, Makris A, Reinhold VN, De Grazia C, Osathanondh R, Ryan KJ. Metabolism of androstenedione by human ovarian tissues in vitro with particular reference to reductase and aromatase activity. Steroids 1979;34:429-43.
143. Regulation of the menstrual cycle. In: Speroff L, Glass RH, Kase NG, editors. Clinical gynecologic endocrinology and infertility. Baltimore (MD): Williams & Wilkins; 1994. p. 183-230.
144. Gondos B. Surface epithelium of the developing ovary. Possible correlation with ovarian neoplasia. Am J Pathol 1975;81:303-21.
145. Grumbach MM, Conte FA. Disorders of sex differentiation. In: Wilson JD, Foster DW, editors. William's textbook of endocrinology. Philadelphia (PA): W.B. Saunders Co.; 1992. p. 853-951.
146. Schottenfeld D. Testicular cancer. In: Schottenfeld D, Fraumeni FJ, editors. Cancer epidemiology and prevention. New York: Oxford University Press; 1996. p. 1207-19.
147. Labrie F, Luu-The V, Labrie C, et al. Endocrine and intracrine sources of androgens in women: inhibition of breast cancer and other roles of androgens and their precursor dehydroepiandrosterone. Endocr Rev 2003;24:152-82.
148. Bulun SE, Price TM, Aitken J, Mahendroo MS, Simpson ER. A link between breast cancer and local estrogen biosynthesis suggested by quantification of breast adipose tissue aromatase cytochrome P450 transcripts using competitive polymerase chain reaction after reverse transcription. J Clin Endocrinol Metab 1993;77:1622-8.
149. Ross RK, Pike MC, Coetzee GA, et al. Androgen metabolism and prostate cancer: establishing a model of genetic susceptibility. Cancer Res 1998;58:4497-504.
150. Silva EG, Tornos C, Deavers M, Kaisman K, Gray K, Gershenson D. Induction of epithelial neoplasms in the ovaries of guinea pigs by estrogenic stimulation. Gynecol Oncol 1998;71:240-6.
151. Key TJ, Allen NE, Verkaslo PK, Banks E. Energy balance and cancer: the role of sex hormones. Proc Nutr Soc 2001;60:81-9.
152. Casey ML, MacDonald P, Simpson ER. Endocrinological changes of pregnancy. In: Wilson JD, Foster DW, editors. William's textbook of endocrinology. Philadelphia (PA): W.B. Saunders Co.; 1998. p. 977-92.
153. The endocrinology of pregnancy. In: Speroff L, Glass RH, Kase NG, editors. Clinical gynecologic endocrinology and infertility. Baltimore (MD): Williams & Wilkins; 1994. p. 251-91.
154. Yen SSC. Endocrine-Metabolic Adaptations in Pregnancy. In: Yen SSC, Jaffe RB, editors. Reproductive endocrinology: physiology, pathophysiology, and clinical management. Philadelphia (PA): W.B. Saunders Co.; 1991. p. 936-81.
155. Van Gorp T, Amant F, Neven P, Vergote I, Moerman P. Endometriosis and the development of malignant tumours of the pelvis. A review of literature. Best Pract Res Clin Obstet Gynaecol 2004;18:349-71.
156. Zeitoun KM, Bulun SE. Aromatase: a key molecule in the pathophysiology of endometriosis and a therapeutic target. Fertil Steril 1999;72:961-9.
157. Zeleniuch-Jacquotte A, Akhmedkhanov A, Kato I, et al. Postmenopausal endogenous oestrogens and risk of endometrial cancer: results of a prospective study. Br J Cancer 2001;84:975-81.
158. Lukanova A, Lundin E, Micheli A, et al. Circulating levels of sex steroid hormones and risk of endometrial cancer in postmenopausal women. Int J Cancer 2003.
159. Lee KR, Tavassoli FA, Prat J, et al. Tumors of the ovary and peritoneum. In: Tavassoli FA, Devilee P, editors. Tumours of the breast and female genital organs. Lyon (France): IARC Press; 2003. p. 113-216.
160. Johnson MR, Abbas A, Nicolaides KH. Maternal plasma levels of human chorionic gonadotrophin, oestradiol and progesterone in multifetal pregnancies before and after fetal reduction. J Endocrinol 1994;143:309-12.
161. Batra S, Sjoberg NO, Aberg A. Human placental lactogen, estradiol-17β, and progesterone levels in the third trimester and their respective values for detecting twin pregnancy. Am J Obstet Gynecol 1978;131:69-72.
162. Haning RV Jr, Kiggens AJ, Leiheit TL. Maternal serum progesterone, 17 β-estradiol and estriol are increased in pregnancies which follow treatment with human menopausal gonadotropins: effects of multiple gestation and maternal endocrine status. J Steroid Biochem 1985;22:823-9.
163. Jawan B, Lee JH, Chong ZK, Chang CS. Spread of spinal anaesthesia for caesarean section in singleton and twin pregnancies. Br J Anaesth 1993;70:639-41.
164. Gilfillan CP, Robertson DM, Burger HG, Leoni MA, Hurley VA, Martin NG. The control of ovulation in mothers of dizygotic twins. J Clin Endocrinol Metab 1996;81:1557-62.
165. Rodriguez GC, Walmer DK, Cline M, et al. Effect of progestin on the ovarian epithelium of macaques: cancer prevention through apoptosis? J Soc Gynecol Investig 1998;5:271-6.
166. Rodriguez GC, Nagarsheth NP, Lee KL, et al. Progestin-induced apoptosis in the Macaque ovarian epithelium: differential regulation of transforming growth factor-β. J Natl Cancer Inst 2002;94:50-60.
167. Bu SZ, Yin DL, Ren XH, et al. Progesterone induces apoptosis and upregulation of p53 expression in human ovarian carcinoma cell lines. Cancer 1997;79:1944-50.
168. Brenner PF, Mishell DR Jr, Stanczyk FZ, Goebelsmann U. Serum levels of D-norgestrel, luteinizing hormone, follicle-stimulating hormone, estradiol, and progesterone in women during and following ingestion of combination oral contraceptives containing DL-norgestrel. Am J Obstet Gynecol 1977;129: 133-140.
169. Rosenberg L, Palmer JR, Zauber AG, et al. A case-control study of oral contraceptive use and invasive epithelial ovarian cancer. Am J Epidemiol 1994:139:654-61.
170. Kumle M, Weiderpass E, Braaten T, Adami HO, Lund E. Risk for invasive and borderline epithelial ovarian neoplasias following use of hormonal contraceptives: the Norwegian-Swedish Women's Lifestyle and Health Cohort Study. Br J Cancer 2004;90:1386-91.
171. Schildkraut JM, Calingaert B, Marchbanks PA, Moorman PG, Rodriguez GC. Impact of progestin and estrogen potency in oral contraceptives on ovarian cancer risk. J Natl Cancer Inst 2002;94:32-8.
172. Moore MA, Park CB, Tsuda H. Implications of the hyperinsulinaemia- diabetes-cancer link for preventive efforts. Eur J Cancer Prev 1998;7:89-107.
173. Giovannucci E. Insulin and colon cancer. Cancer Causes Control 1995;6:164-79.
174. Schoen RE, Tangen CM, Kuller LH, et al. Increased blood glucose and insulin, body size, and incident colorectal cancer. J Natl Cancer Inst 1999;91:1147-54.
175. Kaaks R, Toniolo P, Akhmedkhanov A, et al. Serum C-peptide, insulin-like growth factor (IGF)-I, IGF-binding proteins, and colorectal cancer risk in women. J Natl Cancer Inst 2000;92:1592-600.
176. Troisi R, Potischman N, Hoover RN, Siiteri P, Brinton LA. Insulin and endometrial cancer. Am J Epidemiol 1997;146:476-82.
177. Lukanova A, Zeleniuch-Jacquotte A, Lundin E, et al. Prediagnostic levels of C-peptide, IGF-I, IGFBP-1, -2 and -3 and risk of endometrial cancer. Int J Cancer 2004;108:262-8.
178. Kaaks R, Lukanova A. Energy balance and cancer: the role of insulin and insulin-like growth factor-I. Proc Nutr Soc 2001;60:91-106.
179. Weiderpass E, Ye W, Vainio H, Kaaks R, Adami HO. Diabetes mellitus and ovarian cancer (Sweden). Cancer Causes Control 2002;13:759-64.
180. Adler AI, Weiss NS, Kamb ML, Lyon JL. Is diabetes mellitus a risk factor for ovarian cancer? A case-control study in Utah and Washington (United States). Cancer Causes Control 1996;7:475-8.
181. Wideroff L, Gridley G, Mellemkjaer L, et al. Cancer incidence in a population-based cohort of patients hospitalized with diabetes mellitus in Denmark. J Natl Cancer Inst 1997;89:1360-5.
182. Lukanova A, Lundin E, Micheli A, et al. Risk of ovarian cancer in relation to prediagnostic levels of C-peptide, insulin-like growth factor binding proteins-1 and -2 (USA, Sweden, Italy). Cancer Causes Control 2003;14:285-92.
183. Yu H, Rohan T. Role of the insulin-like growth factor family in cancer development and progression. J Natl Cancer Inst 2000;92:1472-89.
184. Wang HS, Chard T. IGFs and IGF-binding proteins in the regulation of human ovarian and endometrial function. J Endocrinol 1999;161:1-13.
185. Giudice LC. Growth factor action on ovarian function in polycystic ovary syndrome. Endocrinol Metab Clin North Am 1999;28:325-39.
186. Coppola D, Saunders B, Fu L, Mao W, Nicosia SV. The insulin-like growth factor 1 receptor induces transformation and tumorigenicity of ovarian mesothelial cells and down-regulates their Fas-receptor expression. Cancer Res 1999;59:3264-270.
187. Lund PK. Insulin-like growth factors: gene structure and regulation. In: Kostyo JL, Goodman HM, editors. Hormonal control of growth. New York: Oxford University Press; 1999. p. 537-71.
188. Byrne C, Colditz GA, Willett WC, Speizer FE, Pollak M, Hankinson SE. Plasma insulin-like growth factor (IGF) I, IGF-binding protein 3, and mammographic density. Cancer Res 2000;60:3744-8.
189. Hankinson SE, Willett WC, Colditz GA, et al. Circulating concentrations of insulin-like growth factor-I and risk of breast cancer. Lancet 1998;351:1393-6.
190. Toniolo P, Bruning PF, Akhmedkhanov A, et al. Serum insulin-like growth factor-I and breast cancer. Int J Cancer 2000;88:828-32.
191. Juul A. Serum levels of insulin-like growth factor I and its binding proteins in health and disease. Growth Horm IGF Res 2003;13:113-70.
192. Jernstrom H, Deal C, Wilkin F, et al. Genetic and nongenetic factors associated with variation of plasma levels of insulin-like growth factor-I and insulin-like growth factor-binding protein-3 in healthy premenopausal women. Cancer Epidemiol Biomarkers Prev 2001;10:377-84.
193. Fujita M, Enomoto T, Murata Y. Genetic alterations in ovarian carcinoma: with specific reference to histological subtypes. Mol Cell Endocrinol 2003:202:97-9.
194. Emons G, Fleckenstein G, Hinney B, Huschmand A, Heyl W. Hormonal interactions in endometrial cancer. Endocr Relat Cancer 2000;7:227-42.
195. Cardillo MR, Petrangeli E, Aliotta N, et al. Androgen receptors in ovarian tumors: correlation with oestrogen and progesterone receptors in an immunohistochemical and semiquantitative image analysis study. J Exp Clin Cancer Res 1998;17:231-7, 1998.
196. Khandwala HM, McCutcheon IE, Flyvbjerg A, Friend KE. The effects of insulin-like growth factors on tumorigenesis and neoplastic growth. Endocr Rev 2000;21:215-44.
197. Li AJ, Baldwin RL, Karlan BY. Estrogen and progesterone receptor subtype expression in normal and malignant ovarian epithelial cell cultures. Am J Obstet Gynecol 2003;189:22-7.
198. Lau KM, Mok SC, Ho SM. Expression of human estrogen receptor-α and - β, progesterone receptor, and androgen receptor mRNA in normal and malignant ovarian epithelial cells. Proc Natl Acad Sci U S A 1999;96:5722-7.
199. Pujol P, Rey JM, Nirde P, et al. Differential expression of estrogen receptor-α and -β messenger RNAs as a potential marker of ovarian carcinogenesis. Cancer Res 1998;58:5367-73.
200. Brandenberger AW, Tee MK, Jaffe RB. Estrogen receptor α (ER-α) and β (ER-β) mRNAs in normal ovary, ovarian serous cystadenocarcinoma and ovarian cancer cell lines: down-regulation of ER-β in neoplastic tissues. J Clin Endocrinol Metab 1998;83:1025-8.
201. Rutherford T, Brown WD, Sapi E, Aschkenazi S, Munoz A, Mor G. Absence of estrogen receptor-β expression in metastatic ovarian cancer. Obstet Gynecol 2000;96:417-21.